MARKET

AEZS

AEZS

Aeterna Zentaris
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.060
+0.140
+15.22%
After Hours: 1.160 +0.1 +9.43% 19:58 03/08 EST
OPEN
0.9600
PREV CLOSE
0.9200
HIGH
1.160
LOW
0.9350
VOLUME
12.35M
TURNOVER
--
52 WEEK HIGH
3.620
52 WEEK LOW
0.2900
MARKET CAP
123.23M
P/E (TTM)
-5.8402
1D
5D
1M
3M
1Y
5Y
Global Zoladex Market Size 2021 Industry Recent Developments, Emerging Trends, Growth, Progression Status, Latest Technology, and Forecast Research Report 2025
Mar 08, 2021 (The Expresswire) -- Global “Zoladex Market” report is extensive significant analyses of the Zoladex industry and provides data for making...
The Express Wire · 20h ago
Zoladex Market Report 2021 Growth Factors, Research Methodology With Impact of COIVD-19 and Global Forecast 2025
The Express Wire · 3d ago
Global Zoladex Market Size 2021, Top Countries Segmented by Applications and Geography Trends, Emerging Factors On Demand, Growth, Revenue, Market Impact and Precise Outlook 2026
Mar 01, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The global “Zoladex Market” Research...
The Express Wire · 03/01 09:16
Making A List Of Top Penny Stocks? 4 To Buy For Under $3
Feb 24, 2021 (Penny Stocks via COMTEX) -- Cheap Penny Stocks To Buy For Under $3 But Are They Too High Risk? There are plenty of penny stocks to choose from....
Penny Stocks · 02/24 21:10
Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference
GlobeNewswire · 02/24 13:05
Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the closing of its previously announced public offering o...
GlobeNewswire · 02/22 18:34
Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares
GlobeNewswire · 02/19 18:25
SNDL, IMUX among premarket losers
Interpace Biosciences (IDXG) -28%. on Nasdaq delisting.Seanergy Maritime SHIP -23% on capital raise.KAR Auction Services KAR -22% on Q4 earnings.AIkido Pharma AIKI -20% on capital raise.Socket Mobile (SCKT) -20%.ALJ Regional (ALJJ) -17%.Immunic IMUX -17% d...
Seekingalpha · 02/17 13:39
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AEZS. Analyze the recent business situations of Aeterna Zentaris through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AEZS stock price target is 4.500 with a high estimate of 4.500 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 43
Institutional Holdings: 1.29M
% Owned: 1.11%
Shares Outstanding: 116.26M
TypeInstitutionsShares
Increased
4
38.75K
New
10
10.84K
Decreased
2
596.61K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.02%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Independent Director
Carolyn Egbert
President/Chief Executive Officer/Director
Klaus Paulini
Chief Financial Officer/Senior Vice President
Leslie Auld
Vice President - Finance
Guenther Grau
Vice President
Nicola Ammer
Vice President
Matthias Gerlach
Vice President - Business Development
Eckhard Gunther
Director
Gilles Gagnon
Independent Director
Robin Hoke
Independent Director
Brent Norton
No Data
About AEZS
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Webull offers kinds of AEterna Zentaris Inc. (USA) stock information, including NASDAQ:AEZS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEZS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AEZS stock methods without spending real money on the virtual paper trading platform.